A phase 2, open-label, randomized, 2-way crossover, clinical trial to compare the pharmacokinetics of 2 formulations of 'intended commercial product' Technosphere insulin inhalation powder and to determine the bioavailability of a 30 unit cartridge of `intended commercial product' Technosphere insulin inhalation powder versus a 10 unit subcutaneous injection of insulin lispro in subjects with type 1 diabetes mellitus

Trial Profile

A phase 2, open-label, randomized, 2-way crossover, clinical trial to compare the pharmacokinetics of 2 formulations of 'intended commercial product' Technosphere insulin inhalation powder and to determine the bioavailability of a 30 unit cartridge of `intended commercial product' Technosphere insulin inhalation powder versus a 10 unit subcutaneous injection of insulin lispro in subjects with type 1 diabetes mellitus

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2014

At a glance

  • Drugs Insulin; Insulin lispro
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors MannKind Corporation
  • Most Recent Events

    • 27 Jun 2010 Results reported at Amercian Diabetes Association (ADA) meeting, according to a MannKind Corporation media release.
    • 17 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top